Page 1 of 38
PHARMACEUTICAL SALES CERTIFICATION (PSC)
EXAMINATION 2026 COMPLETE (110) CURRENT TESTING
QUESTIONS AND CORRECT ANSWERS WITH DETAILED
RATIONALES.
(PSC)
Prepare for the Pharmaceutical Sales Certification (PSC) Examination with this
comprehensive practice resource designed to support your certification preparation.
It features exam-style questions covering pharmaceutical industry fundamentals,
medication knowledge, sales strategies, healthcare compliance, communication
skills, and ethical sales practices. Use it to reinforce essential concepts, assess your
knowledge, and build confidence before test day. An excellent study aid for
candidates pursuing the Pharmaceutical Sales Certification (PSC).
MULTIPLE CHOICE.
PHARMACEUTICAL INDUSTRY & MARKET DYNAMICS (Questions 1–15)
Question 1: What percentage of total U.S. healthcare expenditures does
prescription drug spending represent?
A. 3–5%
B. 8–10%
C. 15–20%
D. 25–30%
Correct answer: B. 8–10%
Rationale: Prescription and non-prescription drugs represent about 8–10% of
total U.S. healthcare spending, yet are responsible for dramatic reductions in
hospitalization and long-term care costs .
Question 2: What percentage of global pharmaceutical revenues does the
United States account for?
A. 25–30%
B. 35–40%
, Page 2 of 38
C. 45–50%
D. 55–60%
Correct answer: C. 45–50%
Rationale: The U.S. captures about 48–50% of global pharmaceutical sales
due to higher pricing, faster adoption of new therapies, and a large insured
population .
Question 3: What is the estimated fully capitalized cost to bring a new
molecular entity (NME) to market?
A. $500 million–$1 billion
B. $1–$1.5 billion
C. $2.6–$2.9 billion
D. $5–$6 billion
Correct answer: C. $2.6–$2.9 billion
Rationale: According to the Tufts Center for the Study of Drug Development,
the fully capitalized cost is estimated at $2.6–$2.9 billion per approved new
drug, with only about 1 in 5,000–10,000 screened compounds reaching FDA
approval .
Question 4: For every how many compounds screened, approximately how
many receive FDA approval?
A. 1 in 100
B. 1 in 500
C. 1 in 1,000–2,000
D. 1 in 5,000–10,000
Correct answer: D. 1 in 5,000–10,000
Rationale: The drug development process is extremely inefficient; the vast
majority of compounds fail in preclinical or clinical testing due to safety or
efficacy issues .
, Page 3 of 38
Question 5: What is the single most important driver of pharmaceutical
industry revenue growth?
A. Emerging market expansion
B. Increased life expectancy and the aging population
C. New drug pricing strategies
D. Direct-to-consumer advertising
Correct answer: B. Increased life expectancy and the aging population
Rationale: The aging baby-boomer population drives demand for chronic
therapies in oncology, cardiology, neurology, rheumatology, and diabetes .
Question 6: By 2035, how large is the Medicare-eligible population projected
to be?
A. 50 million
B. 65 million
C. 75 million
D. Nearly 85 million
Correct answer: D. Nearly 85 million
Rationale: Medicare beneficiaries have 3–4 times higher per-capita drug
spending than commercially insured populations. The wave of baby boomers
turning 65 continues to drive spending on high-cost specialty medications .
Question 7: Which department is considered the "engine of innovation" in
pharmaceutical companies?
A. Marketing
B. Sales
C. Research & Development (R&D)
D. Legal and Compliance
Correct answer: C. Research & Development (R&D)
Rationale: R&D is the "engine of innovation" responsible for discovering and
inventing new drug candidates .
, Page 4 of 38
Question 8: Pharmaceutical sales are highest in which geographical regions?
A. South America and Africa
B. The U.S., Western Europe, and Japan
C. Southeast Asia only
D. Eastern Europe and Russia
Correct answer: B. The U.S., Western Europe, and Japan
Rationale: These regions have the highest pharmaceutical sales due to
advanced healthcare infrastructure, higher per capita spending, and
established pharmaceutical markets .
Question 9: Prescription drug therapy is NOT cost-effective for insurance
companies and healthcare providers. (T/F)
A. True
B. False
Correct answer: B. False
Rationale: Prescription drug therapy IS cost-effective because it reduces
hospitalizations, emergency room visits, and surgical procedures, ultimately
lowering overall healthcare costs .
Question 10: The high price of healthcare is explained by the high price of
medicines. (T/F)
A. True
B. False
Correct answer: B. False
Rationale: Prescription drugs account for only about 10% of total U.S.
healthcare spending. Hospital and physician services drive most healthcare
costs .
Question 11: Which of the following is NOT a healthcare product category in
the pharmaceutical/life sciences industry?
A. Pharmaceuticals
PHARMACEUTICAL SALES CERTIFICATION (PSC)
EXAMINATION 2026 COMPLETE (110) CURRENT TESTING
QUESTIONS AND CORRECT ANSWERS WITH DETAILED
RATIONALES.
(PSC)
Prepare for the Pharmaceutical Sales Certification (PSC) Examination with this
comprehensive practice resource designed to support your certification preparation.
It features exam-style questions covering pharmaceutical industry fundamentals,
medication knowledge, sales strategies, healthcare compliance, communication
skills, and ethical sales practices. Use it to reinforce essential concepts, assess your
knowledge, and build confidence before test day. An excellent study aid for
candidates pursuing the Pharmaceutical Sales Certification (PSC).
MULTIPLE CHOICE.
PHARMACEUTICAL INDUSTRY & MARKET DYNAMICS (Questions 1–15)
Question 1: What percentage of total U.S. healthcare expenditures does
prescription drug spending represent?
A. 3–5%
B. 8–10%
C. 15–20%
D. 25–30%
Correct answer: B. 8–10%
Rationale: Prescription and non-prescription drugs represent about 8–10% of
total U.S. healthcare spending, yet are responsible for dramatic reductions in
hospitalization and long-term care costs .
Question 2: What percentage of global pharmaceutical revenues does the
United States account for?
A. 25–30%
B. 35–40%
, Page 2 of 38
C. 45–50%
D. 55–60%
Correct answer: C. 45–50%
Rationale: The U.S. captures about 48–50% of global pharmaceutical sales
due to higher pricing, faster adoption of new therapies, and a large insured
population .
Question 3: What is the estimated fully capitalized cost to bring a new
molecular entity (NME) to market?
A. $500 million–$1 billion
B. $1–$1.5 billion
C. $2.6–$2.9 billion
D. $5–$6 billion
Correct answer: C. $2.6–$2.9 billion
Rationale: According to the Tufts Center for the Study of Drug Development,
the fully capitalized cost is estimated at $2.6–$2.9 billion per approved new
drug, with only about 1 in 5,000–10,000 screened compounds reaching FDA
approval .
Question 4: For every how many compounds screened, approximately how
many receive FDA approval?
A. 1 in 100
B. 1 in 500
C. 1 in 1,000–2,000
D. 1 in 5,000–10,000
Correct answer: D. 1 in 5,000–10,000
Rationale: The drug development process is extremely inefficient; the vast
majority of compounds fail in preclinical or clinical testing due to safety or
efficacy issues .
, Page 3 of 38
Question 5: What is the single most important driver of pharmaceutical
industry revenue growth?
A. Emerging market expansion
B. Increased life expectancy and the aging population
C. New drug pricing strategies
D. Direct-to-consumer advertising
Correct answer: B. Increased life expectancy and the aging population
Rationale: The aging baby-boomer population drives demand for chronic
therapies in oncology, cardiology, neurology, rheumatology, and diabetes .
Question 6: By 2035, how large is the Medicare-eligible population projected
to be?
A. 50 million
B. 65 million
C. 75 million
D. Nearly 85 million
Correct answer: D. Nearly 85 million
Rationale: Medicare beneficiaries have 3–4 times higher per-capita drug
spending than commercially insured populations. The wave of baby boomers
turning 65 continues to drive spending on high-cost specialty medications .
Question 7: Which department is considered the "engine of innovation" in
pharmaceutical companies?
A. Marketing
B. Sales
C. Research & Development (R&D)
D. Legal and Compliance
Correct answer: C. Research & Development (R&D)
Rationale: R&D is the "engine of innovation" responsible for discovering and
inventing new drug candidates .
, Page 4 of 38
Question 8: Pharmaceutical sales are highest in which geographical regions?
A. South America and Africa
B. The U.S., Western Europe, and Japan
C. Southeast Asia only
D. Eastern Europe and Russia
Correct answer: B. The U.S., Western Europe, and Japan
Rationale: These regions have the highest pharmaceutical sales due to
advanced healthcare infrastructure, higher per capita spending, and
established pharmaceutical markets .
Question 9: Prescription drug therapy is NOT cost-effective for insurance
companies and healthcare providers. (T/F)
A. True
B. False
Correct answer: B. False
Rationale: Prescription drug therapy IS cost-effective because it reduces
hospitalizations, emergency room visits, and surgical procedures, ultimately
lowering overall healthcare costs .
Question 10: The high price of healthcare is explained by the high price of
medicines. (T/F)
A. True
B. False
Correct answer: B. False
Rationale: Prescription drugs account for only about 10% of total U.S.
healthcare spending. Hospital and physician services drive most healthcare
costs .
Question 11: Which of the following is NOT a healthcare product category in
the pharmaceutical/life sciences industry?
A. Pharmaceuticals
